Baricitinib or imatinib in hospitalized COVID‐19 patients: Results from COVINIB, an exploratory randomized clinical trial
Journal of Medical Virology · 2023-02 · 95 (2)
DOI: 10.1002/jmv.28495 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Medical Virology, online erschienen am 19.01.2023. Verfasst von Alejandro Morales-Ortega und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Baricitinib and imatinib are considered therapies for coronavirus disease 2019 (COVID‐19), but their ultimate clinical impact remains to be elucidated, so our objective is to determine whether these kinase inhibitors provide benefit when added to standard care in hospitalized COVID‐19 patients. Phase‐2, open‐label, randomized trial with a pick‐the‐winner design conducted from September 2020 to June 2021 in a single Spanish center. Hospitalized adults with COVID‐19 pneumonia and a symptom duration ≤10 days were assigned to 3 arms: imatinib (400 mg qd, 7 days) plus standard‐care, baricitinib (4 mg qd, 7 days) plus standard‐care, or standard‐care alone. Primary outcome was time to clinical improvement (discharge alive or a reduction of 2 points in an ordinal scale of clinical status) compared on a day‐by‐day basis to identify differences ≥15% between the most and least favorable groups. Secondary outcomes included oxygenation and ventilatory support requirements, additional therapies administered, all‐cause mortality, and safety. One hundred and sixty‐five patients analyzed. Predefined criteria for selection of the most advantageous arm were met for baricitinib, but not for imatinib. However, no statistically significant differences were observed in formal analysis, but a trend toward better results in patients receiving baricitinib was found compared to standard care alone (hazard ratio [HR] for clinical improvement: 1.41, 95% confidence intervals [CI]: 0.96−2.06; HR for discontinuing oxygen: 1.46, 95% CI: 0.94−2.28). No differences were found regarding additional therapies administered or safety. Baricitinib plus standard care showed better results for hospitalized COVID‐19 patients, being the most advantageous therapeutic strategy among those proposed in this exploratory clinical trial.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain.
- Department of Medicine, Universidad de Alcalá, Madrid, Spain.
- Department of Intensive Care Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain.
- Primary Health Care Center Castilla La Nueva, Madrid, Spain.
- Department of Orthopaedic Surgery and Traumatology, Hospital Universitario de Fuenlabrada, Madrid, Spain.
- Department of Medical Specialties and Public Health, Universidad Rey Juan Carlos, Madrid, Spain.
ORCID-Profile: José Manuel Ruiz-Giardín, Miguel Ángel Duarte-Millán, David Bernal-Bello
Zitieren
APA
Morales-Ortega, A., Farfán-Sedano, A. I., San Martín-López, J. V., Escribá-Bárcena, A., Jaenes-Barrios, B., Madroñal-Cerezo, E., Llarena-Barroso, C., Mesa-Plaza, N., Frutos-Pérez, B., Ruiz-Giardín, J. M., Duarte-Millán, M. Á., Piedrabuena-García, S. I., Carpintero-García, L., Canalejo-Castrillero, E., Mora-Hernández, B., García-Parra, C. J., Magro-García, H. A., Algaba-García, A., Hernández-Muniesa, B., …, & COVINIB Study Group investigators (2023). Baricitinib or imatinib in hospitalized COVID‐19 patients: Results from COVINIB, an exploratory randomized clinical trial. Journal of Medical Virology, 95(2). https://doi.org/10.1002/jmv.28495
Vancouver
Morales-Ortega A, Farfán-Sedano AI, San Martín-López JV, Escribá-Bárcena A, Jaenes-Barrios B, Madroñal-Cerezo E, et al. Baricitinib or imatinib in hospitalized COVID‐19 patients: Results from COVINIB, an exploratory randomized clinical trial. Journal of Medical Virology. 2023;95(2). doi:10.1002/jmv.28495
BibTeX
@article{MoralesOrtega2023,
author = {Morales-Ortega, Alejandro and Farfán-Sedano, Ana Isabel and San Martín-López, Juan Víctor and Escribá-Bárcena, Almudena and Jaenes-Barrios, Beatriz and Madroñal-Cerezo, Elena and Llarena-Barroso, Cristina and Mesa-Plaza, Nieves and Frutos-Pérez, Begoña and Ruiz-Giardín, José Manuel and Duarte-Millán, Miguel Ángel and Piedrabuena-García, Sara Isabel and Carpintero-García, Lorena and Canalejo-Castrillero, Eduardo and Mora-Hernández, Belén and García-Parra, Carlos Javier and Magro-García, Héctor Agustín and Algaba-García, Alicia and Hernández-Muniesa, Belén and Nasarre-López, Berta and Ontañón-Nasarre, Ana and Domínguez-García, María Jesús and Gómez-Santos, Dulce and Prieto-Menchero, Santiago and García de Tena, Jaime and Bermejo, Fernando and García-Gil, Mario and Gonzalo-Pascua, Sonia and Bernal-Bello, David and COVINIB Study Group investigators, COVINIB Study Group investigators},
title = {Baricitinib or imatinib in hospitalized COVID‐19 patients: Results from COVINIB, an exploratory randomized clinical trial},
journal = {Journal of Medical Virology},
year = {2023},
volume = {95},
number = {2},
doi = {10.1002/jmv.28495}
}
EUVIMED